DOCSLIB.ORG

HIV/AIDS Technologies: a Review of Progress to Date and Current Prospects

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
HIV/AIDS Technologies: a Review of Progress to Date and Current Prospects Working Paper No.6 HIV/AIDS Technologies: A review of progress to date and current prospects COMMISSIONED BY: aids2031 Science and Technology Working Group AUTHORED BY: KEITH ALCORN NAM Publications Disclaimer: The views expressed in this paper are those of the author(s) and do not necessarily reflect the official policy, position, or opinions of the wider aids2031 initiative or partner organizations aids2031 Science and Technology working group A review of progress to date and current prospects October 2008 Acronyms 3TC lamivudine ANRS Agènce Nationale de Récherche sur la Sida ART Antiretroviral therapy ARV Antiretroviral AZT azidothymidine or zidovudine bDNA branched DNA CDC US Centers for Disease Control CHER Children with HIV Early Antiretroviral therapy (study) CTL Cytotoxic T-lymphocyte D4T stavudine DSMB Data and Safety Monitoring Board EFV Efavirenz ELISA Enzyme Linked Immunosorbent Assay FDC Fixed-dose combination FTC Emtricitabine HAART Highly Active Antiretroviral Therapy HBAC Home-based AIDS care HCV Hepatitis C virus HPTN HIV Prevention Trials Network HSV-2 Herpes simplex virus type 2 IAVI International AIDS Vaccine Initiative IL-2 Interleukin-2 LED Light-emitting diode LPV/r Lopinavir/ritonavir MIRA Methods for Improving Reproductive Health in Africa trial MSF Médecins sans Frontières MSM Men who have sex with men MVA Modified vaccinia Ankara NIH US National Institutes of Health NRTI Nucleoside reverse transcriptase inhibitor NNRTI Non-nucleoside reverse transcriptase inhibitor OBT Optimised background therapy PCR Polymerase chain reaction PEPFAR President’s Emergency Plan for AIDS Relief PEP Post-exposure prophylaxis PrEP Pre-exposure prophylaxis SIV Simian immunodeficiency virus SMART Strategies for Management of Antiretroviral Therapy TAG Treatment Action Group VOICE Vaginal and Oral Interventions to Control the Epidemic trial ii 1 Contents 1 Contents .................................................................................iii 2 Introduction.............................................................................1 3 Prevention technologies ........................................................3 3.1.1 ‘Combination prevention’ ........................................................................................................... 4 3.1.2 A new lexicon for biomedical HIV prevention? ............................................................................ 4 3.1.3 Future questions for biomedical prevention trials........................................................................ 5 3.1.4 Challenges in biomedical HIV prevention trials ........................................................................... 6 3.1.5 Behavioural prevention ................................................................................................................ 7 3.2 Male condoms.................................................................................................................................. 8 3.3 Harm reduction for injecting drug users .........................................................................................11 3.3.1 Future research questions......................................................................................................... 12 3.4 Circumcision................................................................................................................................... 12 3.4.1 Projected effect on the HIV epidemic ........................................................................................ 13 3.4.2 Circumcision technologies ......................................................................................................... 14 3.4.3 Future research questions......................................................................................................... 16 3.5 Microbicides ................................................................................................................................... 17 3.5.1 How they work ........................................................................................................................... 18 3.5.2 The “first generation” of microbicides: surfactants..................................................................... 19 3.5.3 The “second-generation” of microbicides: non-specific entry inhibitors .................................... 19 3.5.4 The “next generation” of microbicides: specific inhibitors.......................................................... 20 3.5.5 Enhancers of natural defences.................................................................................................. 22 3.5.6 Combination microbicides.......................................................................................................... 22 3.5.7 Rectal microbicides.................................................................................................................... 23 3.5.8 Future research questions......................................................................................................... 23 3.6 Other female-initiated barrier methods ..........................................................................................24 3.6.1 Female condoms ....................................................................................................................... 25 3.6.2 Future research questions......................................................................................................... 25 3.7 Antiretroviral prevention: Pre-exposure prophylaxis (PrEP) .......................................................... 26 3.7.1 Premature halting of early studies ............................................................................................. 27 3.7.2 Public health implications of PrEP............................................................................................. 28 3.7.3 Future research questions......................................................................................................... 28 3.8 Antiretroviral prevention: Post-exposure prophylaxis .................................................................... 29 3.8.1 Effectiveness of post-exposure prophylaxis .............................................................................. 30 iii 3.8.2 Drawbacks of post-exposure prophylaxis.................................................................................. 30 3.8.3 Guidelines for post-exposure prophylaxis ................................................................................. 30 3.8.4 Future research questions......................................................................................................... 30 3.9 Antiretroviral prevention: Antiretroviral treatment of index partners .............................................. 31 3.9.1 Future research questions......................................................................................................... 32 3.10 Prevention of mother-to-child transmission (PMTCT).................................................................... 32 3.10.1 Antiretroviral therapy and prophylaxis ................................................................................ 33 3.10.2 Infant feeding......................................................................................................................... 34 3.11 Sexually transmitted infection treatment........................................................................................37 3.11.1 HSV-2 suppression ...............................................................................................................37 3.11.2 Future research questions..................................................................................................... 39 3.12 Vaccines......................................................................................................................................... 40 3.12.1 Future research questions..................................................................................................... 41 3.12.2 Current investments in vaccine development ....................................................................... 42 4 Antiretroviral treatment........................................................46 4.1 Existing drug classes ..................................................................................................................... 47 4.1.1 Developmental products in existing/emerging classes.............................................................. 48 4.2 Longer-term class developments................................................................................................... 50 4.3 Formulation developments............................................................................................................. 51 4.3.1 Fixed-dose co-formulations ....................................................................................................... 51 4.3.2 Fixed-dose combinations: Paediatric formulations.................................................................... 52 4.3.3 Extended-release products........................................................................................................ 52 4.3.4 Dose reduction........................................................................................................................... 53 4.3.5 Nanotechnology and therapeutics (improved delivery methods) .............................................. 53 4.4 Immunotherapy .............................................................................................................................
Load more

Recommended publications
  • CONFERENCE Summary Report ORGANIZING PARTNERS
    CONFERENCE Summary Report ORGANIZING PARTNERS Convened by: International Partners until we end aids Asia and the Pacific Partners (Regional) Australian Partners (Local) napwha national association of people with hiv australia SPONSORS AND SUPPORTERS Destination Sponsors Major Industry Sponsors Corporate Sponsors Platinum Sponsors Gold Sponsors Silver Sponsor Bronze Sponsors casslogo 10/7/02 1:38 PM Page 1 Donors Foreign Aairs, Trade and Aaires étrangères, Commerce C A S S Development Canada et Développement Canada Contributing to Australian Scholarship & Science AIDS FUND Sustainable Communities With Support From © 2014 Copyright International AIDS Society (IAS) Reproduction, adaptation or translation without prior written permission is prohibited, except as allowed under the copyright laws. Photographs: International AIDS Society (IAS) James Braund Elisabetta Fino Steve Forrest Samantha Sagona International AIDS Society 23 Avenue de France CH 1202 Geneva, Switzerland Tel: +41 22 710 08 00 Fax: +41 22 710 08 99 Email: [email protected] 1 Remembrance The opening of the 20th International AIDS Conference (AIDS 2014) in Melbourne, Australia, was overshadowed by the attack on Malaysia Airlines flight MH17. Six delegates travelling to the conference were among those killed, including Professor Joep Lange, a former President of the International AIDS Society (IAS) and a pioneer in bringing affordable antiretroviral therapy to people living in resource-limited countries. Also killed were Pim de Kuijer (lobbyist Aids Fonds/STOP AIDS NOW!), Lucie van Mens (of the Female Health Company), Martine de Schutter (Program Manager Aids Fonds/STOP AIDS NOW), Glenn Thomas (of the World Health Organization), and Jacqueline van Tongeren (Amsterdam Institute for Global Health and Development).
    [Show full text]
  • Download Article PDF/Slides
    Kan Lu, PharmD New Antiretrovirals for Based on a presentation at prn by Roy M. Gulick, md, mph the Treatment of HIV: Kan Lu, PharmD | Drug Development Fellow University of North Carolina School of Pharmacy Chapel Hill, North Carolina The View in 2006 Roy M. Gulick, md, mph Reprinted from The prn Notebook® | october 2006 | Dr. James F. Braun, Editor-in-Chief Director, Cornell Clinical Trials Unit | Associate Professor of Medicine, Meri D. Pozo, PhD, Managing Editor. Published in New York City by the Physicians’ Research Network, Inc.® Weill Medical College of Cornell University | New York, New York John Graham Brown, Executive Director. For further information and other articles available online, visit http://www.prn.org | All rights reserved. ©october 2006 substantial progress continues to be made in the arena of cokinetics and a long extracellular half-life of approximately 10 hours antiretroviral drug development. prn is again proud to present its annual (Zhu, 2003). During apricitabine’s development, a serious drug interac- review of the experimental agents to watch for in the coming months and tion with lamivudine (Epivir) was noted. Although the plasma years. This year’s review is based on a lecture by Dr. Roy M. Gulick, a long- concentrations of apricitabine were unaffected by coadministration of time friend of prn, and no stranger to the antiretroviral development lamivudine, the intracellular concentrations of apricitabine were reduced pipeline. by approximately sixfold. Additionally, the 50% inhibitory concentration To date, twenty-two antiretrovirals have been approved by the Food (ic50) of apricitabine against hiv with the M184V mutation was increased and Drug Administration (fda) for the treatment of hiv infection.
    [Show full text]
  • Nnrtis – MK1439 New Classes • Maturation Inhibitors, LEDGINS, Etc
    New Antiretrovirals and New Strategies Saye Khoo HIV Pharmacology Group Declaration of Interests •www.hiv-druginteractions.org & www.hep-druginteractions.org sponsorship from Janssen, ViiV, Abbott, Merck, BMS, Gilead, Boehringer, Vertex. Editorial content remains independent. •Research Grants: Merck, ViiV •Speakers bureau: Merck, Janssen, Abbott, Roche •Travel grants: Gilead, ViiV, BMS, Janssen •TaiLor trial (NIHR-funded) Antiretroviral Stewardship Myocardial Infarction Stroke Cancer Congnitive impairment Liver, renal etc Plan Now For Then • what to give ? • Minimise resistance • when to start ? • Minimise toxicity • how to manage ? • Preserve options • Normalise Immunity • Equip for future co-morbidity New Drugs, New Formulations, New Strategies Improvements on existing classes • TAF • dolutegravir and other integrases • new NNRTIs – MK1439 New Classes • Maturation inhibitors, LEDGINS, etc New Formulations • nanoformulations • mono- or dual therapy • LA injections or implants • targeting latent reservoirs New Strategies • NRTI-sparing, PI monotherapy • targeting latent reservoirs • targeting immune activation, cardiovascular risk • etc INSTIs NRTIs PIs NNRTIs Other Approved Dolutegravir Phase 3 TAF DRVc Doravirine TAF/FTC/EVGc (MK1349) Cenicriviroc RPV-LA BMS663068 Phase 2 GSK126744 Racivir ABC/3TC/DTG Amodoxovir TAF/FTC/DRVc Elvucitabine Doravirine (MK-1439) • Pharmacology – Potent - IC95 ~19 nM (50% human serum) – Once-daily dosing; T½ 10-16h – P450 metabolism (CYP3A4/5) • No significant inhibition/induction of CYP P450s • No significant
    [Show full text]
  • Multi-Class Immune-Based Therap I Es Co Combination Drugs AZ T
    m- IMMUNE-BASED THERAP o /R) c VIR, A LPV ) MULTI-CLASSA NFV VIR, A S T N (INDIN COMBINATION DRUGSA VIR, REZIST AZ R 754) P A ) AVX C + Inhibitors Protease RTV VIR/RITON ) CRIXIV AB A OM (KIVEXA, COMBIVIR (ZIDOVUDINE + LAMIVUDINE, AZT + 3TC) EMTRIVA Protease754, Inhibitors C VIR, (EMTRICITABINE, FTC) EPIVIR (LAMIVUDINE, 3TC) EPZICOM (KIVEXA, TPV T A PZI HE EPT (NELFIN SPD OVIR DISOPROXIL ABACAVIR + LAMIVUDINE, ABC + 3TC) RETROVIR (ZIDOVUDINE, AZT, E HIBITO F VIR, , LOPIN ZDV) TRIZIVIR (ABACAVIR + ZIDOVUDINE + LAMIVUDINE, ABC + AC A A S IR N IN TRUGGLE FOR AZT + 3TC) TRUVADA (TENOFOVIR DF + EMTRICITABINE, TDF + V ENO A ) T ABINE ( ABINE FTC) VIDEX & VIDEX EC (DIDANOSINE, DDI) VIREAD (TENOFOVIR T TV I THE (ALUVI C DISOPROXIL FUMARATE, TDF) ZERIT (STAVUDINE, D4T) ZIAGEN A (ABACAVIR, ABC) RACIVIR (RCV) AMDOXOVIR (AMDX, DAPD) ORVIR (RITON N PRI VIR, A ) IREAD ( A A V APRICITABINE (SPD754, AVX754)ELVUCITABINE (ACH- TORS ) LETR N ) A I 126,443, BETA-L-FD4C) COMBIVIR (ZIDOVUDINE + FPV A Z I LAMIVUDINE, AZT + 3TC) EMTRIVA (EMTRICITABINE, ) K A ) APTIVUS (TIPR DAPD T VIR, IPTASE IPTASE , A FTC) EPIVIR (LAMIVUDINE, 3TC) EPZICOM (KIVEXA, A PV A SQV CCESS TO ABACAVIR + LAMIVUDINE, ABC + 3TC) RETROVIR R Z ( PIVIR (LAMIVUDINE, 3TC) B A This book documents the struggle that has been faced by those E (ZIDOVUDINE, AZT, ZDV) TRIZIVIR (ABACAVIR + T AMDX VIR, VIR, A A A I STRUGGLEA requiring treatment for HIV/AIDS in India, and those affected ZIDOVUDINE + LAMIVUDINE, ABC + AZT + 3TC) MPREN AVIR + ZIDOVUDINE + LAMIVUDINE, SC EY A C TRUVADA (TENOFOVIR DF + EMTRICITABINE, by HIV/AIDS, since the first recorded incidence of HIV/AIDS in FOR R N ) TDF + FTC) VIDEX & VIDEX EC (DIDANOSINE, QUIN India in 1986.
    [Show full text]
  • AVCC Figure Template
    Schinazi 11/2/08 14:00 Page 343 Antiviral Chemistry & Chemotherapy 18:343–346 Short communication Cellular pharmacology of 9-(β-D-1,3-dioxolan-4-yl) guanine and its lack of drug interactions with zidovudine in primary human lymphocytes Brenda I Hernandez-Santiago, Aleksandr Obikhod, Emilie Fromentin, Selwyn J Hurwitz and Raymond F Schinazi* Center for AIDS Research, Laboratory of Biochemical Pharmacology, Department of Pediatrics, Emory University School of Medicine, and Veterans Affairs Medical Center, Decatur, GA 30033, USA *Corresponding author: Tel: 404 728 7711; Fax: 404 728 7726; E-mail: [email protected] Amdoxovir, currently in Phase II clinical trials, is different resistance mutations, co-formulation of rapidly converted to 9-(β-D-1,3-dioxolan-4- the these two drugs is an attractive proposition. A yl)guanine (DXG) by adenosine deaminase in vitro combination study between DXG and ZDV and in humans. The cellular pharmacology of DXG showed no reduction of DXG-TP or ZDV-TP. Taken in primary human lymphocytes, including together, these results suggest that an appropri- dose–response relationships, intracellular half-life ately designed DXG prodrug could be given once of DXG triphosphate (DXG-TP), and combination a day and that co-formulation with ZDV might be studies were determined. DXG produced high a possibility. levels of DXG-TP with a long half-life (16 h) in acti- vated human peripheral blood mononuclear cells. Keywords: cellular pharmacology, DXG, nucleoside Since zidovudine (ZDV) and DXG select for analogues, NRTI The emergence of resistant HIV strains during therapy has inhibitor of HIV-1, HIV-2 and hepatitis B virus (HBV) made it a major challenge to develop drugs that delay, in human cell lines.
    [Show full text]
  • Innovation in Antiretrovirals to Meet Developing Country Needs
    Meeting Summary: Centre on Global Health Security Innovation in Antiretrovirals to Meet Developing Country Needs July 2011 The views expressed in this document are the sole responsibility of the author(s) and do not necessarily reflect the view of Chatham House, its staff, associates or Council. Chatham House is independent and owes no allegiance to any government or to any political body. It does not take institutional positions on policy issues. This document is issued on the understanding that if any extract is used, the author(s)/ speaker(s) and Chatham House should be credited, preferably with the date of the publication or details of the event. Where this document refers to or reports statements made by speakers at an event every effort has been made to provide a fair representation of their views and opinions, but the ultimate responsibility for accuracy lies with this document’s author(s). The published text of speeches and presentations may differ from delivery. Innovation in Antiretrovirals to Meet Developing Country Needs ACRONYMS 3TC Lamivudine ABC Abacavir ART Antiretroviral treatment ARV Antiretroviral ATV Atazanavir AZT Zidovudine CHAI Clinton Health Access Initiative DNDi Drugs for Neglected Diseases initiative EDCTP European and Developing Countries Clinical Trials Partnership EFV Efavirenz FDC Fixed-dose combination IP Intellectual property HBV Hepatitis B virus HCV Hepatitis C virus HIV Human immunodeficiency virus LPV Lopinavir RTV, r Ritonavir TB Tuberculosis TDF Tenofovir Disoproxil Fumarate UN United Nations WHO World Health Organization www.chathamhouse.org.uk 2 Innovation in Antiretrovirals to Meet Developing Country Needs Background On July 11, 2011, Chatham House, the Medicines Patent Pool, UNITAID and the World Health Organization (WHO), convened an expert meeting to identify the key innovation needs in the field of antiretroviral treatment for resource-limited settings, and to discuss the role of different actors in ensuring that the necessary innovation is undertaken.
    [Show full text]
  • This Project Has Been Supported with Unrestriced Grants from Abbvie Gilead Sciences HEXAL Janssen-Cilag MSD Viiv Healthcare By
    This project has been supported with unrestriced grants from AbbVie Gilead Sciences HEXAL Janssen-Cilag MSD ViiV Healthcare By Marcus Altfeld, Hamburg/Boston (USA) Achim Barmeyer, Dortmund Georg Behrens, Hannover Dirk Berzow, Hamburg Christoph Boesecke, Bonn Patrick Braun, Aachen Thomas Buhk, Hamburg Rob Camp, Barcelona (Spain/USA) Rika Draenert, Munich Christian Eggers, Linz (Austria) Stefan Esser, Essen Gerd Fätkenheuer, Cologne Gunar Günther, Windhoek (Namibia) Thomas Harrer, Erlangen Christian Herzmann, Borstel Christian Hoffmann, Hamburg Heinz-August Horst, Kiel Martin Hower, Dortmund Christoph Lange, Borstel Thore Lorenzen, Hamburg Tim Niehues, Krefeld Christian Noah, Hamburg Ramona Pauli, Munich Ansgar Rieke, Koblenz Jürgen Kurt Rockstroh, Bonn Thorsten Rosenkranz, Hamburg Bernhard Schaaf, Dortmund Ulrike Sonnenberg-Schwan, Munich Christoph D. Spinner, Munich Thomas Splettstoesser (Figures), Berlin Matthias Stoll, Hannover Hendrik Streeck, Essen/Boston (USA) Jan Thoden, Freiburg Markus Unnewehr, Dortmund Mechthild Vocks-Hauck, Berlin Jan-Christian Wasmuth, Bonn Michael Weigel, Schweinfurt Thomas Weitzel, Santiago (Chile) Eva Wolf, Munich HIV 2015/16 www.hivbook.com Edited by Christian Hoffmann and Jürgen K. Rockstroh Medizin Fokus Verlag IV Christian Hoffmann, M.D., Ph.D. ICH Stadtmitte (Infektionsmedizinisches Centrum Hamburg) Glockengiesserwall 1 20095 Hamburg, Germany Phone: + 49 40 2800 4200 Fax: + 49 40 2800 42020 [email protected] Jürgen K. Rockstroh, M.D., Ph.D. Department of Medicine I University of Bonn Sigmund-Freud-Strasse 25 53105 Bonn, Germany Phone: + 49 228 287 6558 Fax: + 49 228 287 5034 [email protected] HIV Medicine is an ever-changing field. The editors and authors of HIV 2015/16 have made every effort to provide information that is accurate and complete as of the date of publication.
    [Show full text]
  • Px Wire: on HIV Prevention Research Volume 1 | No
    A Quarterly Update Px Wire: on HIV Prevention Research Volume 1 | No. 4 October–December 2008 and Phambili studies. The initial results of the Step study AVAC’s Take were published in November 2008 in the Lancet journal (Lancet, doi:10.1016/S0140-6736(08)61591-3). Greetings! This is the last issue of Px Wire in 2008—and what In the Step study, MRK-Ad5 had no overall benefit in terms a year it has been. The AIDS vaccine field has started to move Continues on back ahead with different goals and refined strategies in the wake of disappointing data from 2007. Multiple PrEP trials were launched or expanded, the microbicide field began to focus considerably At a Glance: Moving right along more on the implications of ARV-containing products, and the scale-up of male circumcision started in some countries. • An FDA panel of independent advisors recommended At the International AIDS Conference in August, and approval of the newly formulated female condom (FC2) in a provocative Lancet article (Lancet, doi:10.1016/S0140- in December, green-lighting the less expensive and 6736(08)61697-9) by WHO staff, including Kevin De Cock, physically streamlined second-generation product by director of the HIV/AIDS program, the notion of ARV the Female Health Company. Donors, governments and treatment as prevention seized the spotlight. This newly implementers should take advantage of this lower cost highlighted strategy will continue, we predict, to help shape option and take long overdue action to dramatically the field in 2009. increase access to and information about the female Also in 2009, AVAC will work with other prevention stakeholders condom as part of all HIV prevention and family to put the spotlight on HIV testing, which is the cornerstone planning programs.
    [Show full text]
  • David Cooper Symposium Treatment and Prevention Access for All
    David Cooper Symposium Treatment and prevention access for all Friday 15 June 2018 Science Theatre, Kensington Campus, UNSW Sydney 8:00am Registration 9:00am Welcome to Country 9:05am Welcome Symposium Professor Ian Jacobs, President and Vice-Chancellor, UNSW Sydney opening 9:10am Opening Senator the Hon Lisa Singh, Co-chair of the Parliamentary Group on HIV/AIDS and Chairs: Blood-borne Viruses Professor John Kaldor, Professor Anthony 9:20am Video message Kelleher The Hon Greg Hunt, Minister for Health 9:25am From molecules to populations Professor Anthony Kelleher 9:40am Special Presentation 9:50am Brett Tindall Lecture: Ending AIDS in Thailand Professor Emeritus Praphan Phanuphak 10:20am Adult and paediatric infectious diseases clinical trial networks in Africa – challenges, impact, future directions Dr Sarah Pett 10:35am Morning Tea 11:00am The role of research in global health Session 2 H. Clifford Lane M.D. Chairs: 11:30am A HIV test and treat initiative in Indonesia: the HATI project Mr Bill Bowtell, Professor Matthew Law Associate Professor 11:45am Building laboratory support for translational research in our region Allison Imrie Associate Professor Philip Cunningham 12:00pm A reflection on community engagement with HIV research Ms Jo Watson 12:15pm Lunch 1:05pm AIDS is (STILL) political Session 3 Professor Linda-Gail Bekker 1:35pm HIV and ageing: a long journey Chairs: Professor Brian Gazzard Professor Janaki Amin, Dr Mark Polizzotto 2:05pm Coops, co-morbidities and the pursuit of safe, lifelong therapy for HIV Dr Patrick Mallon
    [Show full text]
  • Background Paper 6.7 Human Immunodeficiency Virus (HIV)/ Acquired Immune Deficiency Syndromes (AIDS)
    Priority Medicines for Europe and the World "A Public Health Approach to Innovation" Update on 2004 Background Paper Written by Warren Kaplan Background Paper 6.7 Human Immunodeficiency Virus (HIV)/ Acquired Immune Deficiency Syndromes (AIDS) By Warren Kaplan, Ph.D., JD, MPH 15 February 2013 Update on 2004 Background Paper, BP 6.7 HIV/AIDS Table of Contents What is new since 2004? ..................................................................................................................................... 4 1. Introduction ................................................................................................................................................. 7 2. What are the Epidemiological Trends for Europe and the World? ................................................... 7 2.1 Western and Central Europe ............................................................................................................. 7 2.2 Eastern Europe .................................................................................................................................... 9 2.2 The World (including Europe) ........................................................................................................ 11 3. What is the Control Strategy? Is There an Effective Package of Control Methods Assembled into a “Control Strategy” for Most Epidemiological Settings?................................................................. 13 3.1 Is there a pharmaceutical ‘gap’? ....................................................................................................
    [Show full text]
  • INTEREST 2018 Summary Overview
    INTEREST Conference 2018 Summary The INTEREST Story Known as the “African CROI”, the annual INTEREST Conference brings together scientists involved in HIV treatment, pathogenesis, and prevention research in resource- limited settings from around the world. The INTEREST Conference provides a platform to share pivotal fi ndings, promote collaboration, and transfer experiences across several fi elds and continents. The fi rst INTEREST Conference was Health and Development (AIGHD) Health Diane Gashumba. Conference held in 2007 in Uganda and it is held and Professor Charles Boucher co-chairs Professor Cate Hankins, in an African country each year. The of Erasmus University. AIGHD, and Dr. Elly Katabira, conference brings together world- Professor of Medicine in the School renowned HIV experts and young INTEREST 2018 of Medicine, Makerere University African researchers with an overall College of Health Sciences, Uganda goal of building the next generation The 2018 INTEREST Conference was worked closely with the 2018 local of African scientists and facilitating held in Kigali, Rwanda at the Kigali chair, Dr. Sabin Nsanzimana of networking opportunities. Convention Centre from May 29 the Rwanda Biomedical Center INTEREST was co-founded by the to June 1. The event was offi cially to execute the most successful late Professor Joep Lange of the opened by a presentation from The INTEREST Conference in its 12-year Amsterdam Institute for Global Honourable Rwanda Minister of history. INTEREST 2018 by the numbers Social Media Summary Countries represented
    [Show full text]
  • A Better State of ART Improving Antiretroviral Regimens to Increase Global Access to HIV Treatment
    Journal of AIDS and HIV Research Vol. 3(4), pp. 71-78, April 2011 Available online http:// academicjournals.org/JAHR ISSN 2141-2359 ©2011 Academic Journals Review A better state of ART improving antiretroviral regimens to increase global access to HIV treatment Matthew Barnhart 1* and James Shelton 2 1UNICEF Programme Division, Health Section, New York, New York, USA. 2USAID/Washington Bureau for Global Health, Washington DC, USA. Accepted 04 March, 2011 With 5.2 million people already receiving antiretroviral therapy (ART) in low and middle-income countries and 33.4 million people estimated to be living with HIV globally, there is an urgent need to develop better antiretroviral (ARV) regimens that are less costly and less complex to implement than the current standard of care. We think it is technically possible to develop such improved regimens soon, and discuss some illustrative examples of how new ARVs and treatment simplification approaches might simultaneously improve outcomes and dramatically reduce costs. Such regimens would: 1) include new ARVs that are more tolerable, durable, and inexpensive to manufacture; 2) contain a reduced number of ARVs; and/or 3) be amenable to directly observed dosing on a weekly or a monthly-basis. However, success will not only require technical solutions, but also good will and mechanisms to foster collaboration within the international community. Therefore, we also suggest a few priority actions that interested parties can take to help expedite the widespread availability of better ARV regimens. Key words: HIV treatment, antiretroviral drugs, manufacturing costs, corporate social responsibility, incentives for research and development. THE COMPELLING NEED FOR MORE AND BETTER ANTIRETROVIRAL THERAPY Despite herculean success in providing antiretroviral “atripla” (efavirenz, tenofovir disoproxil fumarate, therapy (ART) to 5.2 million people in low and middle- emtricitabine), the most commonly used first-line regimen income counties (LMICs) of the 33.4 million people living in affluent countries, costs $200 per patient year.
    [Show full text]